Compare GPGI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPGI | PRAX |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.6B |
| IPO Year | N/A | N/A |
| Metric | GPGI | PRAX |
|---|---|---|
| Price | $23.61 | $330.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $519.60 |
| AVG Volume (30 Days) | ★ 2.2M | 494.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.53 | N/A |
| Revenue Next Year | $9.95 | $38,343.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.24 | $26.70 |
| 52 Week High | $26.78 | $335.75 |
| Indicator | GPGI | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 42.60 | 60.92 |
| Support Level | $21.60 | $314.35 |
| Resistance Level | $25.66 | $335.75 |
| Average True Range (ATR) | 1.28 | 15.86 |
| MACD | 0.01 | -0.33 |
| Stochastic Oscillator | 49.51 | 87.81 |
GPGI Inc is a diversified holding platform comprising businesses operating in multiple industries. The platform focuses on acquiring, owning, and scaling operating companies. It currently includes CompoSecure and Husky Technologies. CompoSecure provides technology and manufacturing solutions related to metal payment cards, security, and authentication. Its products and services are used by financial institutions, fintech companies, and other customers. Husky designs and manufactures industrial equipment and provides aftermarket services. Its equipment is used in the production of plastic products, including beverage and food containers, medical devices, and consumer electronics components.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.